Buccal Dexmedetomidine (Reconnect Labs)

右美托咪定口腔制剂 (Reconnect Labs)

Report date: 2025/01/17 16:38:52

Base Information

Drug NameBuccal Dexmedetomidine (Reconnect Labs)
Drug Alias NameRE-03RE03
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors alpha-2 agonists
TargetsAdrenergic receptors alpha-2
Therapy Area/IndicationsStress Disorders, Post-TraumaticSleep Initiation and Maintenance Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesReconnect Labs
China Registration ClassN/A

Develop Information

Active CompaniesReconnect Labs
Inactive CompaniesN/A
Active IndicationsStress Disorders, Post-TraumaticSleep Initiation and Maintenance Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A